[Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children]

[Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children] Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

[Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children] Abstract Text:

C Gaillez,F Sorbara,E Perrin,C Gaillez,F Sorbara,E Perrin,

INTRODUCTION: Atomoxetine (Strattera) is the first non-stimulant drug to be approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children 6 years of age and adolescents. Atomoxetine is a highly specific inhibitor of the presynaptic norepinephrine transporter, with minimal affinity for other transporters or other neurotransmitter receptors. The target dose is 1.2 mg/kg, in a once- or twice-daily oral administration. CLINICAL DATA: Six randomized, double blind, placebo-controlled clinical trials have demonstrated that atomoxetine was more effective than placebo for the treatment of children and adolescents with ADHD. All these trials have shown a consistent improvement in the ADHD rating scale (ADHD-RS) from baseline in the patients treated with atomoxetine, compared with that of the placebo group. The improvement of ADHD symptoms was confirmed by the other secondary efficacy measures (the Clinical Global Impression, CGI, the Conners ADHD rating scale/parent, teacher). The duration of action of atomoxetine on ADHD symptoms extended throughout the waking hours, and the drug effects persisted up to the next morning with a single morning dose. Significant improvements were also observed with atomoxetine compared to placebo, in several aspects of the quality of life measurement (social and family functioning), and the child's self-esteem. In addition, in patients who responded favourably to initial treatment, atomoxetine was shown to be superior to placebo in maintaining a long term-response, up to 18 months. Atomoxetine was effective and safe, both in young children and adolescents with ADHD. Preliminary data also support the potential efficacy of atomoxetine in managing patients with ADHD and comorbid conditions, such as tic disorders, oppositional-defiant and conduct disorders. DISCUSSION: As of June 2004, over 3,000 children and adolescents have been enrolled in clinical trials of atomoxetine, with about 1,200 of them treated for more than 1 year and about 400 of them treated for more than 2 years. Atomoxetine was well tolerated in most individuals, the two more common adverse events reported were gastro-intestinal disorders and decreased appetite. These side effects were generally noted to be transient. No significant changes in weight and height gain was reported over the long-term follow-up. There was no evidence of symptoms rebound and no evidence of an acute discontinuation syndrome when discontinuing treatment. In addition, given the mechanism of action of atomoxetine in the central nervous system, and lack of subjective, physiological and psychomotor effects reported in experimental conditions, it is unlikely that atomoxetine would have abuse potential. CONCLUSION: Results from clinical trials demonstrated that atomoxetine is effective and well tolerated for the acute and long-term treatment of children and adolescents suffering from ADHD. Atomoxetine should be considered as a new interesting pharmacological option in the treatment of ADHD in association with non pharmacological therapeutic interventions.

[Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children] Publishing Authors By Initials

C Gaillez,F Sorbara,E Perrin,C Gaillez,F Sorbara,E Perrin,

For similar organic chemicals: amines: propylamines research abstracts see: organic chemicals: amines: propylamines research

PUBMED ID PMID:

MEDLINE DATE:

[Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children] Journal Published:

PUBLICATION TYPE: Randomized Controlled Trial

Journal: L'Encéphale

VOLUME: 33

Page Numbers: 621-8

Journal Abbreviation:

ISSN: 0013-7006

DAY: 19

MONTH: Sep

YEAR: 2007

[Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children] Information

Number of References:

LANGUAGE: fre

NlmUniqueID: 7505643

[Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children] Keywords Mesh Terms:

KEYWORDS: Propylamines

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children] Information

Substance Name: atomoxetine

Registry Number: 83015-26-3

Grant and Affiliation Information for [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children]

AFFILIATION: Département Médical, Unité thérapeutique Système Nerveux Central, Laboratoires Lilly France, 13, rue Pagès, 92158 Suresnes cedex.

Country: France

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Encephale

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Atomoxetine Strattera, an alternative in the treatment of attention-deficit/hyperactivity disorder ADHD in children Related Publications

• A microcalorimetric investigation of the binding of flurbiprofen to cyclodextrins.
• Analysis of some dosage forms containing pyridine derivatives using a cyclodextrin bonded stationary phase in HPLC.
• Arylfluoroborates and alkylfluorosilicates as potential PET imaging agents: high-yielding aqueous biomolecular 18F-labeling.
• Assembly of hexamolybdenum metallic clusters on silicon surfaces.
• Carnitine is associated with fatty acid metabolism in plants.
• Cognitive processing and motor skill learning in motor-handicapped teenagers: Effects of learning method.
• Cognitive task fulfilment may decrease gaze control performances.
• Drosophila aging 2005/06.
• Editorial comment on: The immediate and 6-mo reproducibility of pressure-flow studies in men with benign prostatic enlargement.
• Evaluation of exposure with response-prevention for obsessive compulsive disorder in childhood and adolescence.
• Histopathologic observations in a fatal case of Q fever.
• In search of peer reviewers.
• Information technology to support improved care for chronic illness.
• Measurement of flurbiprofen-human serum albumin interaction by fluorimetry.
• Microcalorimetric and chromatographic investigations of the binding of some pyridine derivatives to cyclodextrins.
• Net energy of cellulosic ethanol from switchgrass.
• Pyruvate reduces DNA damage during hypoxia and after reoxygenation in hepatocellular carcinoma cells.
• SCHIP, Children, and Politics.
• Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test.
• Signalling pathways involved in adult heart formation revealed by gene expression profiling in Drosophila.
• Simultaneous determination of codeine and ibuprofen in plasma by high-performance liquid chromatography.
• The independent and interactive effects of navicular drop and quadriceps angle on neuromuscular responses to a weight-bearing perturbation.
• Toward an RNaseA mimic: A DNAzyme with imidazoles and cationic amines.
• Triggering DNAzymes with light: a photoactive C8 thioether-linked adenosine.
• Tryptathionine bridges in peptide synthesis.
• Unusual coexistence of magnetic and nonmagnetic Mo6 octahedral clusters in a chalcohalide solid solution: synthesis, X-ray diffraction, EPR, and DFT investigations of Cs3Mo6Ii6Ii2-xSeixIa6.
• [In Process Citation]
• [Not Available.]
• [Not Available.]
• [Not Available.]